Effectiveness of colesevelam hydrochloride in decreasing LDL cholesterol in patients with primary hypercholesterolemia: a 24-week randomized controlled trial

Mayo Clinic Proceedings
W InsullM H Davidson

Abstract

To evaluate the efficacy, tolerability, and safety of colesevelam hydrochloride, a new nonsystemic lipid-lowering agent. In this double-blind, placebo-controlled trial performed in 1998, 494 patients with primary hypercholesterolemia (low-density lipoprotein [LDL] cholesterol level > or = 130 mg/dL and < or = 220 mg/dL) were randomized to receive placebo or colesevelam (2.3 g/d, 3.0 g/d, 3.8 g/d, or 4.5 g/d) for 24 weeks. Fasting serum lipid profiles were measured to assess efficacy. Adverse events were monitored, and discontinuation rates and compliance rates were analyzed. The primary outcome measure was the mean absolute change of LDL cholesterol from baseline to the end of the 24-week treatment period. Colesevelam lowered mean LDL cholesterol levels 9% to 18% in a dose-dependent manner (P<.001), with a median LDL cholesterol reduction of 20% at 4.5 g/d. The reduction in LDL cholesterol levels was maximal after 2 weeks and sustained throughout the study. Mean total cholesterol levels decreased 4% to 10% (P<.001), while median high-density lipoprotein cholesterol levels increased 3% to 4% (P<.001). Median triglyceride levels increased by 5% to 10% in placebo and colesevelam treatment groups relative to baseline (P<.05), but n...Continue Reading

References

Jul 15, 1992·The American Journal of Cardiology·H R SuperkoJ L Probstfield
Nov 1, 1972·The Journal of Clinical Investigation·J T Garbutt, T J Kenney
May 29, 1980·The New England Journal of Medicine·J ShepherdH G Morgan
Jan 9, 1995·Archives of Internal Medicine·M A Denke
May 26, 1998·JAMA : the Journal of the American Medical Association·J AvornJ LeLorier
Dec 22, 1998·The American Journal of Cardiology·B G Brown, X Q Zhao
May 23, 2001·JAMA : the Journal of the American Medical Association·UNKNOWN Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults

❮ Previous
Next ❯

Citations

Apr 29, 2010·Current Diabetes Reports·Bart StaelsVivian Fonseca
Apr 27, 2010·Diabetes, Obesity & Metabolism·Vivian A FonsecaBart Staels
Sep 28, 2006·Annual Review of Physiology·David Q-H Wang
Dec 22, 2010·Lipids in Health and Disease·Krishnaswami Vijayaraghavan
Jan 1, 2009·Diabetes, Metabolic Syndrome and Obesity : Targets and Therapy·Ronald B Goldberg
May 4, 2011·World Journal of Diabetes·Kohzo TakebayashiToshihiko Inukai
Aug 29, 2013·Nature Reviews. Gastroenterology & Hepatology·Frank G SchaapPeter L M Jansen
Apr 30, 2014·Drugs & Aging·James R GavinKenneth E Truitt
Nov 27, 2009·Postgraduate Medicine·Yehuda HandelsmanMichael R Jones
May 24, 2006·Expert Review of Cardiovascular Therapy·Annemarie Armani, Peter P Toth
Apr 12, 2008·Expert Review of Cardiovascular Therapy·Roeland HuijgenBarbara A Hutten
Oct 31, 2003·Expert Opinion on Investigational Drugs·Pedro Iglesias, Juan J Díez
Dec 10, 2003·Expert Opinion on Emerging Drugs·Anthony S Wierzbicki
Oct 13, 2007·Expert Opinion on Pharmacotherapy·Michael H Davidson
Mar 22, 2012·Expert Opinion on Drug Metabolism & Toxicology·Lisa M Younk, Stephen N Davis
Oct 27, 2004·Expert Opinion on Investigational Drugs·Anthony S Wierzbicki
May 13, 2003·Expert Opinion on Pharmacotherapy·Harold Bays, Carlos Dujovne
Feb 18, 2011·Expert Opinion on Emerging Drugs·Matilda FlorentinMoses S Elisaf
Nov 2, 2006·Current Medical Research and Opinion·Harold BaysMichael Jones
Feb 23, 2008·Current Medical Research and Opinion·M FlorentinM S Elisaf
Aug 29, 2006·Journal of Pharmaceutical Sciences·Martin Hanus, Eugene Zhorov
Jan 1, 2012·Scientifica·Giuseppe Danilo Norata
Mar 24, 2009·Clinical Therapeutics·Travis E SonnettStephen M Setter
Feb 17, 2009·Endocrinology and Metabolism Clinics of North America·Runhua Hou, Anne Carol Goldberg
Mar 5, 2008·Mayo Clinic Proceedings·Paresh Dandona
Jun 1, 2008·Journal of Clinical Lipidology·Barry Browne, Susie Vasquez
May 4, 2005·Cardiovascular Drug Reviews·Karen L Steinmetz, Kristine S Schonder
Oct 4, 2003·Pharmacotherapy·Paul D Thompson
May 14, 2003·Pharmacotherapy·Chad R Worz, Michael Bottorff
Feb 20, 2013·European Journal of Clinical Investigation·Helen H WangDavid Q-H Wang
Aug 5, 2010·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·Edith M M KuiperHenk R van Buuren
Sep 18, 2004·The American Journal of Cardiology·Antonios M XydakisChristie M Ballantyne
Sep 27, 2005·Reproductive Toxicology·Judith K MarquisMichael R Jones
Aug 23, 2006·The American Journal of Cardiology·Sridevi DevarajIshwarlal Jialal
Dec 9, 2014·American Journal of Therapeutics·Constantine E Kosmas, William H Frishman
Oct 10, 2014·Atherosclerosis·Alberico L CatapanoAndrew M Tershakovec
Feb 25, 2009·European Journal of Cardiovascular Prevention and Rehabilitation : Official Journal of the European Society of Cardiology, Working Groups on Epidemiology & Prevention and Cardiac Rehabilitation and Exercise Physiology·Alberto CorsiniMichel Farnier
Dec 22, 2011·Current Opinion in Lipidology·Carolien OutGemma Brufau
Aug 5, 2011·Journal of Pharmacy Practice·Luigi Brunetti, R Keith Campbell

❮ Previous
Next ❯

Related Concepts

Related Feeds

Carcinoma, Basal Cell

Basal cell carcinoma is a form of malignant skin cancer found on the head and neck regions and has low rates of metastasis. Discover the latest research on basal cell carcinoma here.

ApoE, Lipids & Cholesterol

Serum cholesterol, triglycerides, apolipoprotein B (APOB)-containing lipoproteins (very low-density lipoprotein (VLDL), immediate-density lipoprotein (IDL), and low-density lipoprotein (LDL), lipoprotein A (LPA)) and the total cholesterol/high-density lipoprotein (HDL) cholesterol ratio are all connected in diseases. Here is the latest research.